GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, NexImmune’s Chief Executive Officer, participated and presented a corporate update at:

Jefferies Healthcare Conference
Thursday, June 6th, 4:00PM ET
New York, NY
The presentation will be Available for 90 days

VIEW PRESENTATION

NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. For more information visit: www.neximmune.com